Phase 3 N=29 An Endometrial Cancer Chemoprevention Study of Metformin
Gynecology
Primary: To Evaluate the Participant Body Weight in Pounds (Lbs) — 108.57; 99.3; 101.64; 94.1 lbs — p=0.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=90 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Atopic Dermatitis
Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (≥75% Reduction From Baseline in EASI) at Week 16 — 69.2 percentage of participants
Phase 3 N=141 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Heterozygous
Primary: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) — -27.14; 1.40 percent change in LDL-C — p=<.0001
Phase 3 N=15 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
Tricuspid Regurgitation
Primary: Procedural Success — 42.86 Percentage of Participants
Phase 3 N=229 Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
HIV Infections · Streptococcus Pneumoniae
Primary: Positive Immune Responses in the Human Immunodeficiency Virus (HIV)-Infected Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPV) Arms…
Phase 3 N=26 24 Hour Ambulatory Cardiac Oxygen Consumption
Hypertension
Primary: ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI) — 2531; 2824; 2484 mmHg*beats/min — p=0.05
Phase 3 N=99 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Chronic Plaque Psoriasis · Moderate to Severe Nail Psoriasis
Primary: The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28. — 0.042; 0.255 proportion of subjects — p=0.00311
Phase 3 N=410 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Phase 3 N=145 Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Primary: Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control Group — 42.9; 16.9 score on scale…
Phase 3 N=601 Metabolism Informed Smoking Treatment: The MIST RCT
Smoking
Primary: Biochemically-validated Past 7-day Point Prevalence Tobacco Abstinence — 54; 49 Participants — p=0.461
Phase 3 N=355 Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
Glabellar Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
Phase 3 N=698 Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
Breast Cancer
Primary: Progression-free Survival — 4.8; 4.1; 3.5 Months — p=0.76
Phase 3 N=986 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] — -0.81; -0.72 Percentage of HbA1c
Phase 3 N=333 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
Presbyopia
Primary: Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated Subjects — 27…
Phase 3 N=755 Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
Hypertension
Primary: Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4 — -9.6; -10.4; -2.2 mmHg — p=<0.0001